Article

From ASCO: Updates in HER2-positive breast cancers

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Related Videos
1 expert is featured in this series.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Related Content
FDA approves Ryoncil for children with GVHD.
December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of a woman with her hand hovering over a laptop keyboard.
December 18th 2024

How to Get the Most from Patient Portals During a Cancer Journey

Alex Biese
An expert advises a few things to keep in mind when patients with cancer are navigating these platforms.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of doctor consulting man.
December 18th 2024

Understanding Prostate Cancer Treatment Side Effects Is Key

Ashley Chan
A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on the appropriate options.
Image of red blood cells.
December 18th 2024

Imbruvica-Venetoclax Shows Promise in Managing CLL

Spencer Feldman
A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.